Recursion Pharmaceuticals, Inc.
RXRX
Positions held
Your positionsRXRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Recursion Pharmaceuticals is leveraging its innovative approach to biotechnology, focusing on data-driven drug discovery, which positions it well in a competitive industry.
- Revenue increased by 16% compared to the prior quarter, reaching $7.3 million.
- Gross margin improved to -57.3%, a significant recovery from -98.2% in the previous quarter.
- The company faces significant financial challenges, including a high debt-to-equity ratio of 7.283, indicating potential liquidity issues.
- Operating margin remains severely negative at -1848.1%, reflecting ongoing operational inefficiencies.
- Net income for the most recent quarter was -131.005 million, continuing a trend of substantial losses.
Fundamentals
| Market cap | $2.12B | Enterprise value | $1.64B | Trailing P/E | — | Forward P/E | -4.38 |
| PEG | — | Price / book | 2.31 | Beta | 1.03 | Dividend yield | 0.00% |
| Revenue growth | -60.1% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -17.6% |
| Profit margin | 0.0% | ROE | -56.6% | ROA | -27.3% | Debt / equity | 0.07 |
| Current ratio | 5.03 | Free cash flow | -$219.49M | Analyst recommendation | none | Mean target | $7.22 |
| 52w high | $7.18 | 52w low | $2.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.3M | $6.3M | $35.4M | $5.0M | $19.1M |
| Op margin | -1848.1% | -2039.4% | -306.5% | -3455.8% | -922.5% |
| Net income | -$131M | -$118M | -$108M | -$162M | -$172M |
| Gross margin | -57.3% | -98.2% | 59.6% | -194.7% | -5.5% |
| Gross profit | -$4.2M | -$6.2M | $21.1M | -$9.7M | -$1.1M |
| Operating income | -$135M | -$129M | -$108M | -$172M | -$176M |
- Revenue +16% vs prior quarter ($7.3M vs $6.3M).
- Gross margin -57.3% (was -98.2% prior quarter).
- Operating margin expanded to -1848.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $74.3M | $58.5M | $43.9M | $39.7M | — |
| Op margin | -872.8% | -819.0% | -797.8% | -619.3% | — |
| Net income | -$645M | -$464M | -$328M | -$239M | — |
| Gross margin | 4.4% | 22.7% | 2.9% | -21.7% | — |
| Gross profit | $3.3M | $13.3M | $1.3M | -$8.6M | — |
| Operating income | -$648M | -$479M | -$350M | -$246M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-10-06 · Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
2026-10-06 · BC-Most Active Stocks
2026-10-06 · Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-05 · Ondas, SoundHound AI Lead Wall Street's Most Shorted Stocks
2026-10-05 · BC-Most Active Stocks
2026-09-28 · Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-09-24 · Analysts move HubSpot 29 places higher in power ranking
2026-09-24 · Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
2026-09-23 · Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
2026-09-22 · Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
2026-09-22 · Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Price (daily)
Full chart · RSI · MACD · patterns